BACKGROUND: We previously showed that Toll-like receptor-9 (TLR-9) ligands ameliorate experimental colitis. In this study, we evaluated the effect of TLR-9 ligands on the generation of proinflammatory cytokines by human colonic mucosa. MATERIALS AND METHODS: Colonoscopic biopsies were obtained from patients with active ulcerative colitis (UC) and from normal subjects. The tissue was organ cultured for 24 hours in the presence or absence of different types of immunostimulatory (ISS) (CpG)-oligonucleotides (ODNs). Tumor necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta) levels in the medium were determined by enzyme-linked immunosorbent assay. RESULTS: In active UC, hTNF-alpha and hIL-lbeta generation by inflamed colonic mucosa is 7- and 3-fold higher, respectively, than their generation by normal mucosa. Class B CpG ODNs inhibited colonic TNF-alpha and IL-1beta generation by 50%, whereas class A or C ODNs had a partial or no effect, respectively. A novel class of ODNs that is based on multiple TCG repeats was as effective as class B ODNs. This inhibition resulted from the transcriptional suppression of IL-1beta that occurred within the first 2 hours after ISS-ODN incubation. The addition of chloroquine abolished the inhibitory effects of ISS-ODNs on colonic TNF-alpha and IL-1beta generation. CONCLUSIONS: Only certain classes of ISS-ODNs inhibit the enhanced TNF-alpha and IL-1beta generated ex vivo by inflamed colonic mucosa of patients with UC. The effect of ISS-ODNs is mediated by triggering of TLR-9. These results suggest a potential therapeutic value for ISS-ODNs in UC.
BACKGROUND: We previously showed that Toll-like receptor-9 (TLR-9) ligands ameliorate experimental colitis. In this study, we evaluated the effect of TLR-9 ligands on the generation of proinflammatory cytokines by human colonic mucosa. MATERIALS AND METHODS: Colonoscopic biopsies were obtained from patients with active ulcerative colitis (UC) and from normal subjects. The tissue was organ cultured for 24 hours in the presence or absence of different types of immunostimulatory (ISS) (CpG)-oligonucleotides (ODNs). Tumor necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta) levels in the medium were determined by enzyme-linked immunosorbent assay. RESULTS: In active UC, hTNF-alpha and hIL-lbeta generation by inflamed colonic mucosa is 7- and 3-fold higher, respectively, than their generation by normal mucosa. Class B CpG ODNs inhibited colonic TNF-alpha and IL-1beta generation by 50%, whereas class A or C ODNs had a partial or no effect, respectively. A novel class of ODNs that is based on multiple TCG repeats was as effective as class B ODNs. This inhibition resulted from the transcriptional suppression of IL-1beta that occurred within the first 2 hours after ISS-ODN incubation. The addition of chloroquine abolished the inhibitory effects of ISS-ODNs on colonic TNF-alpha and IL-1beta generation. CONCLUSIONS: Only certain classes of ISS-ODNs inhibit the enhanced TNF-alpha and IL-1beta generated ex vivo by inflamed colonic mucosa of patients with UC. The effect of ISS-ODNs is mediated by triggering of TLR-9. These results suggest a potential therapeutic value for ISS-ODNs in UC.
Authors: Robert Barrett; Xiaolan Zhang; Hon Wai Koon; Michelle Vu; Jyh-Yau Chang; Nicole Yeager; Mary Ann Nguyen; Kathrin S Michelsen; Dror Berel; Charalabos Pothoulakis; Stephan R Targan; David Q Shih Journal: Am J Pathol Date: 2011-12-02 Impact factor: 4.307
Authors: Julia B Ewaschuk; Jody L Backer; Thomas A Churchill; Florian Obermeier; Denis O Krause; Karen L Madsen Journal: Infect Immun Date: 2007-02-26 Impact factor: 3.441
Authors: Misty Good; Chhinder P Sodhi; John A Ozolek; Rachael H Buck; Karen C Goehring; Debra L Thomas; Amit Vikram; Kyle Bibby; Michael J Morowitz; Brian Firek; Peng Lu; David J Hackam Journal: Am J Physiol Gastrointest Liver Physiol Date: 2014-04-17 Impact factor: 4.052
Authors: Steven C Gribar; Chhinder P Sodhi; Ward M Richardson; Rahul J Anand; George K Gittes; Maria F Branca; Adam Jakub; Xia-hua Shi; Sohail Shah; John A Ozolek; David J Hackam Journal: J Immunol Date: 2009-01-01 Impact factor: 5.422